Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27612366 | 0.82 | POLB (0.47) | POLBALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL19707372 | 0.82 | MAPT (0.47) | POLBALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL1646972 | 0.81 | NAPRT (0.46) | POLBKMT2AMAPTCYP3A4SMN1; SMN2 | |
| SCHEMBL19707314 | 0.81 | POLB (0.54) | POLBALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL11249289 | 0.81 | PDK1 (0.60) | POLBALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL25041715 | 0.80 | NR1H4 (0.51) | MEN1KMT2AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL28130554 | 0.80 | MAPT (0.49) | POLBALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL2950253 | 0.79 | EPHX1 (0.52) | POLBALDH1A1MEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL8791650 | 0.79 | NAPRT (0.45) | POLBKMT2AMAPTCYP3A4SMN1; SMN2 | |
| SCHEMBL2953506 | 0.78 | EPHX1 (0.50) | POLBALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680343-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-21 | — | — | EP | disclosed |
| WO-2024192415-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20190134005-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARM INC (US) | 2019-05-09 | — | — | US | disclosed |
| WO-2017214505-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| EP-1496838-B1 | SUBSTITUTED AMIDES | MERCK SHARP & DOHME (US) | 2010-11-03 | — | — | EP | disclosed |
| US-7816534-B2 | Substituted amides | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090258884-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-7550489-B2 | Substituted pyridyoxy amides | MERCK & CO., INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20080171692-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2008-07-17 | — | — | US | disclosed |
| EP-1496838-A4 | SUBSTITUTED AMIDES | MERCK & CO INC (US) | 2008-07-02 | — | — | EP | disclosed |
| US-6972295-B2 | Substituted amides | MERCK & CO., INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20050234061-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2005-10-20 | — | — | US | disclosed |
| CN-1639112-A | Substituted amides having cannabinoid-1 receptor activity | MERCK & CO INC (US) | 2005-07-13 | — | — | CN | disclosed |
| EP-1496838-A2 | SUBSTITUTED AMIDES | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004048317-A1 | SUBSTITUTED AMIDES ACTIVE AT THE CANNABINOID-1 RECEPTOR | MERCK & CO., INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | MERCK SHARP & DOHME LLC | 2004-03-25 | — | — | US | disclosed |
| WO-2003077847-A2 | SUBSTITUTED AMIDES | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| US-4119633-A | HYPOLIPEMIC, HYPOCHOLESTRIC AGENTS | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1978-10-10 | — | — | US | disclosed |
| US-3979405-A | HYPOLIPEMIC AND HYPOCHOLESTERIC AGENTS | GYOGYSZER- ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171692-A1 | Substituted amides | CNR1, CNR2, FAAH | POLB 1762/4885ALDH1A1 2986/4885MEN1 218/4885 |
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | CNR1, CNR2, MAG | POLB 2132/4885ALDH1A1 3568/4885MEN1 178/4885 |
| US-20090258884-A1 | Substituted amides | CNR1, CNR2, FAAH | POLB 1762/4885ALDH1A1 2986/4885MEN1 218/4885 |
| US-20190134005-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | UGCG, MAN2B1, GBA1 | POLB 1109/4885ALDH1A1 2406/4885MEN1 1675/4885 |
| US-20050234061-A1 | Substituted amides | CNR1, CNR2, FAAH | POLB 1762/4885ALDH1A1 2986/4885MEN1 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.